<DOC>
	<DOCNO>NCT02477527</DOCNO>
	<brief_summary>Switch patient Atripla Stribild evaluate see patient less sleep disturbance .</brief_summary>
	<brief_title>Atripla Stribild Switch Study Evaluate Sleep Disturbances</brief_title>
	<detailed_description>Stribild prefer regimen Department Health Human Services guideline demonstrate non-inferiority Atripla treatment na√Øve patient 144 week ( GS-102 ) . Stribild also statistically significant less Central Nervous System side effect , sleep disturbance lipid elevation compare Atripla . This study evaluate efficacy , safety , change Central Nervous System abnormalities sleep disorder follow switch virologically suppressed subject Atripla Stribild .</detailed_description>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>HIV+ subject 18 year age older estimate Glomerular Filtration Rate &gt; 70 mL/min must currently Atripla take least 3 month HIV1 Viral Load &lt; 50 copies/mL antiretrovirals prior initiation Atripla baseline genotyping pregnancy unable provide inform consent enrol another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>atripla</keyword>
	<keyword>stribild</keyword>
	<keyword>dream</keyword>
</DOC>